Baxter Says 2023 Performance Reflects Strategic Initiatives With New Operating Model Without BioPharma Solutions Unit
Baxter's Q4 2023 results: $3.89 billion revenue, surpassing consensus, 4% Y/Y growth. Strong sales in Medical Products, Therapies, Kidney Care, and Pharmaceuticals segments.